|
Ligand Pharmaceuticals is receptive to new ideas. The drug development company works with gene transcription technology to address assorted illnesses. The company sold off its commercial operations, including its FDA-approved pain drug Avinza, and has refocused on developing a pipeline of new compounds. Its research and development projects include treatments for thrombocytopenia (low platelet count), osteoporosis, menopausal conditions, hepatitis C, cancers, and chronic liver disease, developed internally and in collaboration with larger drug companies. Ligand is expanding its development pipeline through acquisitions.
|
| | | Contact Information | |
Address: |
10275 Science Center Dr.
San Diego, CA 92121-1117
| | Phone: | 858-550-7500 | | Fax: | 858-550-7506 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 27.30 M | | Revenue Growth (1 yr): | 111.80% | | Employees (2008): | 96 | | Employee Growth (1 yr): | 62.70% |
|
|
Key People
| | • |
Chairman:
John W. Kozarich
| | • |
President, CEO, and Director:
John L. Higgins
| | • |
VP Finance and CFO:
John P. Sharp
|
|
|
